Cellectar Biosciences Inc. (CLRB) 正积极推进其临床开发战略,计划在一线治疗失败且已接受过BTK抑制剂治疗的患者群体中,启动一项关键的验证性随机研究。这项研究旨在进一步评估其核心疗法的有效性与安全性,为该药物在更广泛临床场景中的应用提供坚实证据。
公司此举标志着其研发管线的重要进展,目标是为现有治疗方案有限的难治性患者群体探索新的治疗选择。
Cellectar Biosciences Inc. (CLRB) 正积极推进其临床开发战略,计划在一线治疗失败且已接受过BTK抑制剂治疗的患者群体中,启动一项关键的验证性随机研究。这项研究旨在进一步评估其核心疗法的有效性与安全性,为该药物在更广泛临床场景中的应用提供坚实证据。
公司此举标志着其研发管线的重要进展,目标是为现有治疗方案有限的难治性患者群体探索新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.